Interne Geneeskunde


De vakgroep beoefent de interne geneeskunde in de volle breedte.

De vakgroep bestaat uit de volgende sub-specialismen: oncologie, hematologie, nefrologie, vasculaire geneeskunde, algemeen interne, endocrinologie en intensive care.

Er lopen diverse onderzoekslijnen met origineel wetenschappelijk onderzoek. De vakgroep interne geneeskunde verzorgt het perifere deel van de opleiding tot internist (4 jaar) met daarin onder andere de stages oncologie, hematologie en nefrologie. Iedere interne sectie levert topklinische zorg waarbij de patiënt centraal staat. De sfeer in de maatschap is zonder meer open en stimulerend.

 

Leden

dr. E.F.H. (Eric) van Bommel

dr. E.F.H. (Eric) van Bommel

Nefrologie, vasculaire geneeskunde

BIG: 19020116401

J. (Joan) van den Bosch

J. (Joan) van den Bosch

Oncologie

BIG: 89038103301

dr. S.C.C. (Simone) Hartong

dr. S.C.C. (Simone) Hartong

Vasculaire geneeskunde

BIG: 49043157701

dr. R.M. (Rosalie) Kiewiet-Kemper

dr. R.M. (Rosalie) Kiewiet-Kemper

Endocrinologie, obesitas

BIG: 29049211001

J.J.E.M. (Jos) Kitzen

J.J.E.M. (Jos) Kitzen

Oncologie

BIG: 39048440501

dr. M.D. (Mark-David) Levin

dr. M.D. (Mark-David) Levin

Hematologie

BIG: 09046525401

J.A.A. (Ton) Meijer

J.A.A. (Ton) Meijer

Endocrinologie

BIG: 09046061301

dr. M.W.C.J. (Mariëtte) Schoofs

dr. M.W.C.J. (Mariëtte) Schoofs

Endocrinologie

BIG: 19051657201

dr. P.J.H. (Peter) Smak Gregoor

dr. P.J.H. (Peter) Smak Gregoor

Nefrologie, vasculaire geneeskunde

BIG: 89032851501

M. (Marija) Trajkovic

M. (Marija) Trajkovic

Oncologie

BIG: 39064201201

E.J.H.M. (Ernst-Jan) van der Weijgert

E.J.H.M. (Ernst-Jan) van der Weijgert

Algemene interne geneeskunde

BIG: 69024888401

dr. P.E. (Peter) Westerweel

dr. P.E. (Peter) Westerweel

Hematologie, duikgeneeskunde

BIG: 89061093201

dr. E.T. (Elske ) Massolt

dr. E.T. (Elske ) Massolt

Endocrinologie

BIG: 59064796101

E. (Eva ) de Jongh

E. (Eva ) de Jongh

Hematologie

BIG: 19909624101

dr. J.B. (Jeroen) van der Net

dr. J.B. (Jeroen) van der Net

Nefrologie

BIG: 39064434101

dr. E.W. (Esther) Bouman

dr. E.W. (Esther) Bouman

Oncologie

BIG: 49913614401

M. (Marieke) van der Zwan

M. (Marieke) van der Zwan

Nefrologie

BIG: 19912164901

Dordwijk

Publicaties

01jan

Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer.

01jan

Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.

01dec

Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX.

01nov

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.

01nov

The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.

01nov

Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.

01nov

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

01okt

Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial.

01sep

BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.

01aug

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.

01aug

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.

01aug

High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLL.

01aug

Predictors of the corrected count increment after platelet transfusion, a secondary analysis of the PACER randomized controlled trial.

01jul

Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.

01jul

Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study.

01jul

European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: A clinical utility study in the Netherlands

01jun

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit CLL patients.

01mei

Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia.

01mei

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

01mei

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

01mei

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.

01apr

Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome.

01apr

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

01apr

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation.

01mrt

High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population.

01mrt

Risk of cancer after ST-segment-elevation myocardial infarction.

01feb

Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study.

01jan

Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population.

01jan

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.

01dec

Starting home telemonitoring and oxygen therapy directly after emergency department assessment appears to be safe in COVID-19 patients.

01nov

Overall survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR) : a randomized, Open-Label, Phase III Trial.

01nov

Adherence to quality indicators in chronic myeloid leukemia care : results from a population-based study in The Netherlands.

01okt

Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA : the CASSIOPET study.

01aug

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

01aug

Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients.

01aug

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

01aug

Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism.

01aug

Hair Repigmentation Induced by Nilotinib

01aug

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

01jul

Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with Cancer.

01jul

DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.

01jul

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

01jun

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

01jun

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

01mei

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21 R110.

01apr

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018.

01apr

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

01mrt

Clinical significance of soluble interleukin-2 receptor measurement in patients with idiopathic retroperitoneal fibrosis.

01mrt

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

01mrt

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.

01mrt

A Patient with Moderate Intellectual Disability and 49, XXXYY Karyotype.

01mrt

Establishing a Multicenter Network for Patients With Thyroid Nodules and Cancer: Effects on Referral Patterns.

01feb

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry.

01feb

Radiofrequency ablation for benign symptomatic thyroid nodules in the Netherlands: successful introduction of a minimally-invasive treatment option improving quality of life.

01jan

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.

01jan

Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.

Vacatures

Beeldmateriaal

of login met gebruikersnaam